KRAS and colorectal carcinoma: Gene therapy targeting defective genes such as TP53 (tumor suppressor gene encoding p53) and KRAS in CRC may serve as an alternative therapeutic pathway to standard treatment.[8] In conclusion, personalized cancer drugs are becoming increasingly important in colorectal cancer treatment.